JAN 27, 2022 4:00 PM PST

The way to the heart is through the toilet seat. Casana raises $30million for its blood pressure monitoring toilet seat.

WRITTEN BY: J. Bryce Ortiz

Casana, a healthcare company based out of Rochester, New York, announced early this week that it has raised $30 million in funding for its smart toilet seat. The company, whose main mission is to provide effortless, in-home healthcare monitoring for patients with chronic disease, will use the money to help pursue Food and Drug Administration (FDA) clearance for their device. The $30 million in new funding comes a year after Casana announced that it had raised $14 million in initial funding. 

Casana will pursue FDA clearance for its device called The Heart Seat. The Heart Seat aims to be the first-of-its-kind, commercially available cuffless blood pressure monitor built directly into the toilet seat. The Heart Seat can passively capture heart health parameters, such as blood pressure, for individual monitoring, and overcomes issues with other heart rate monitors which lead to poor patient compliance.

At-home healthcare monitoring is a burgeoning market, and the COVID-19 pandemic has placed added value on the ability to monitor one’s own health from home. In fact, recent studies show that the majority of healthcare and healthcare monitoring is migrating from professional healthcare facilities to individuals’ homes. This migration is beneficial for personal health as it allows for easier access to monitoring devices, a reduction in health care costs, and improved comfort for patients. 

Casana aims to join the at-home healthcare monitoring market with its important device. Dr. Jeffrey Leiden, Chairman of the Board of Casana, said, “as healthcare moves from the doctor’s office into the home, convenient home monitoring is becoming increasingly important for patient care.” He continued, “Casana’s Heart Seat holds the unique promise of reliably and conveniently measuring multiple health parameters including Blood Pressure, Heart Rate and Oxygen saturation, all in the privacy of the patient’s home.”

Unlike other blood pressure monitoring devices, the Heart Seat is unique in that it takes no effort or behavior changes to measure the health of your heart. One simply needs to use the toilet, as we all do at least once a day, and the Heart Seat will do the rest of the work. Austin McChord, the CEO of Casana, added, “The Heart Seat is different from virtually every other vitals monitoring produce, in that it takes no time out of your day and works best when you forget it’s even there.” The company is already beginning the process of FDA approval and hopes to begin the sale of the Heart Seat towards the end of the year. 

 

Sources: CasanaBioSpaceCasana Heart SeatYahoo!Home HealthcareHealthline

About the Author
PhD in Neuroscience
Science and medical writer | Researcher | Interested in the intersection between translational science, drug development, and policy
You May Also Like
MAR 18, 2022
Cannabis Sciences
Consensus: Advice for Treating Epilepsy with Cannabis
MAR 18, 2022
Consensus: Advice for Treating Epilepsy with Cannabis
A group of Australian clinical experts have developed consensus advice about medical cannabis recommendations for patien ...
APR 20, 2022
Microbiology
Rapid AST: A key weapon in the fight against AMR
APR 20, 2022
Rapid AST: A key weapon in the fight against AMR
Despite the dire, well-documented risks of antimicrobial resistance (AMR), which threatens to kill 10 million people a y ...
APR 20, 2022
Health & Medicine
The Link between Mental Health and COVID Breakthrough Infection
APR 20, 2022
The Link between Mental Health and COVID Breakthrough Infection
Researchers from University of California San Francisco and the San Francisco Veterans Affairs Health Care System conduc ...
APR 21, 2022
Drug Discovery & Development
No Link Between Antidepressants and Improved Quality of Life
APR 21, 2022
No Link Between Antidepressants and Improved Quality of Life
Those who use antidepressant medications have a similar health-related quality of life to people who are depressed and w ...
MAY 11, 2022
Drug Discovery & Development
Gene Therapy Shows Promise for Neuropathic Pain
MAY 11, 2022
Gene Therapy Shows Promise for Neuropathic Pain
A gene therapy has been able to inhibit neuropathic pain with no detectable side effects in mice with spinal cord and pe ...
MAY 19, 2022
Drug Discovery & Development
Experimental Drug Shows Promise Against ALS
MAY 19, 2022
Experimental Drug Shows Promise Against ALS
A new experimental drug known as NU-9 may be more effective in treating ALS than existing FDA-approved drugs. The corres ...
Loading Comments...